AVID BIOSERVICES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.35 USD | +0.41% |
|
+15.02% | +13.08% |
| 24/04 | Avid Bioservices, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 | CI |
| 19/04 | North American Morning Briefing : Stock Futures -2- | DJ |
| Sales 2024 * | 139M 11.56B | Sales 2025 * | 166M 13.8B | Capitalization | 467M 38.9B |
|---|---|---|---|---|---|
| Net income 2024 * | -16M -1.33B | Net income 2025 * | -4M -334M | EV / Sales 2024 * | 3.37 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.82 x |
| P/E ratio 2024 * |
-28.6
x | P/E ratio 2025 * |
-118
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Avid Bioservices, Inc.
More recommendations
More press releases
| 1 day | +0.41% | ||
| 1 week | +15.02% | ||
| Current month | +9.70% | ||
| 1 month | +5.30% | ||
| 3 months | +8.57% | ||
| 6 months | +19.12% | ||
| Current year | +13.08% |
1 week
6.31
7.68
1 month
6.147.68
Current year
5.658.83
1 year
4.0718.86
3 years
4.0734.51
5 years
3.0234.51
10 years
1.9734.51
| Managers | Title | Age | Since |
|---|---|---|---|
Nicholas Green
CEO | Chief Executive Officer | 60 | 30/20/30 |
Daniel Hart
DFI | Director of Finance/CFO | 50 | 01/18/01 |
Nick Ferguson
CTO | Chief Tech/Sci/R&D Officer | - | 01/99/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregory Sargen
BRD | Director/Board Member | 59 | 27/17/27 |
Joseph Carleone
CHM | Chairman | 78 | 27/17/27 |
Catherine Mackey
BRD | Director/Board Member | 68 | 25/19/25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 7.35 | +0.41% | 1,268,426 |
| 25/24/25 | 7.32 | +7.17% | 1,916,082 |
| 24/24/24 | 6.83 | +2.25% | 1,442,149 |
| 23/24/23 | 6.68 | +4.21% | 702,786 |
| 22/24/22 | 6.41 | +0.31% | 511,100 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services. The Companyâs services include clinical and commercial product manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The Company also provides a variety of process development services, including upstream and downstream development and optimization, analytical methods development, testing and characterization. It provides fully integrated and customized biomanufacturing services that support its customers from the early preclinical stage to commercial launch and supply.
Sector
Pharmaceuticals
Calendar
30/04/2024
- Q3 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.35
USD
Average target price
12.25
USD
Spread / Average Target
+66.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.08% | 467M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- CDMO Stock
